Gomez-Thinnes’ appointment became effective yesterday, Oct. 26, 2022. She joins the San Francisco-based company, which develops prescription digital therapeutics (PDTs). They use a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, including diabetes. The company last month submitted its BT-001 digital therapeutic for type 2 diabetes to the FDA for de novo classification.
Get the full story at our sister site, Drug Delivery Business News.
